APVO Files 8-K Furnishing Press Release on Q2 2025 Financial Results

Rhea-AI Filing Summary

Aptevo Therapeutics announced that it furnished a press release reporting its financial results for the period ended June 30, 2025. The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference into the report. The company states the information is being furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws and will not be incorporated by reference into future SEC filings unless expressly referenced. The 8-K itself contains no financial figures or metrics; readers must consult the attached press release for the reported results.

Insights

Securities Analyst

TL;DR: Routine earnings press release furnished; filing provides no financial figures and limits SEC filing liability.

The 8-K informs investors that Aptevo has furnished a press release with financial results for the period ended June 30, 2025. Because the company explicitly states the release is "furnished, not filed," the disclosure is procedural and does not expand statutory liability under Sections 11, 12(a)(2) or 18. The form contains no revenue, profit, cash flow, or other metrics, so the filing itself does not change observable financial data or valuation assumptions until the attached press release is reviewed.

Corporate Governance Specialist

TL;DR: Administrative 8-K; attachment exists but the report does not create new filed disclosures or governance events.

The report documents issuance of a press release announced via Exhibit 99.1. The company reiterates standard disclosure language that the furnished information will not be incorporated by reference into other SEC filings absent explicit reference. The document is signed by the CEO on behalf of the registrant, but it does not disclose management changes, transactions, or governance actions.

0001671584false00016715842025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the “SEC”) made by the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 11, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	August 11, 2025	By:	/s/ Marvin L. White
			Marvin L. White President and Chief Executive Officer

FAQ

What did Aptevo (APVO) file in this 8-K?

The company furnished a press release announcing financial results for the period ended June 30, 2025, attached as Exhibit 99.1.

Does the 8-K include financial figures for Q2 2025?

No. The 8-K states the press release contains the financial results; the 8-K itself does not include revenue, net income, or other numeric metrics.

Is the press release considered "filed" with the SEC?

No. The filing explicitly states the information is being furnished and shall not be deemed "filed" for purposes of specified securities law liabilities.

Where can investors find the reported financial results?

The reported results are in the press release attached to the 8-K as Exhibit 99.1; the 8-K directs readers to that exhibit for the actual figures.

Who signed the 8-K for Aptevo?

The form is signed on behalf of the registrant by Marvin L. White, President and Chief Executive Officer.